(no text — see the shared post below)

NLA consensus: apoB testing helps when LDL-C and risk are discordant
Summary of a National Lipid Association expert consensus on apoB testing. ApoB counts all atherogenic particles and may predict risk better than LDL-C, especially after statin treatment when the two diverge, and testing is suggested for borderline-risk patients deciding on a statin and in other discordant cases.


